Global University Venturing

Schroder UK Public Private Trust, the rebranded fund previously led by Neil Woodford, has sold its shareholding in Carrick Therapeutics at a discount.

University of British Columbia spinout Paragon Testing Enterprises has agreed to an acquisition by Prometric Canada Testing Services.

University of Oxford, OSI and Parkwalk Advisors all returned for Oxford Endovascular’s $10m series A round.

Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.

The oncology drug developer, backed by Bristol Myers Squibb, secured close to $144m in its IPO. This is an exit from a space that has seen much corporate support over the past decade.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.

UC Berkeley's DNA-editing technology spinout has raised $10m from RA Capital in addition to the $65m it pocketed in November.

RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.

The programme follows a report that MIT missed out on the creation of 40 spinouts over two decades due to lack of engagement with women faculty.